source
- Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demandsBiopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the m…
- FDA signals new window for companies with recent complete response letters after commissioner’s exitAfter FDA Commissioner Marty Makary left, the agency indicated it will reconsider drugs that received complete response letters in the past year. The move offers sponsors a chance to resubmit thei…